Amgen biosimilar matches AbbVie’s Humira in psoriasis trial

Amgen is on track to launch a biosimilar competitor to AbbVie’s Humira – the biggest-selling pharmaceutical product in the world – after positive data in a phase III trial. The biotech major said that in the first of two late-stage studies, its ABP 501 biosimilar was equivalent to Humira (adalimumab) in terms of its efficacy and safety in patients with moderate-to-severe plaque psoriasis after 16 weeks’ treatment.